LATEST RELEASES

UPDATE ON THE MCC RESOLUTION TO WITHDRAW DEXTROPROPOXYPHENE-CONTAINING MEDICINES FROM THE SOUTH AFRICAN MARKET

Further to the announcement released earlier today on SENS, Adcock Ingram would like to advise that the Company has received notification from the Medicines Control Council of the Department of Health ("MCC") relating to the withdrawal of dextropropoxyphene ("DPP") containing medicines from the South African market.

WITHDRAWAL OF DEXTROPROPOXYPHENE-CONTAINING MEDICINES

On 19 November 2010, the US Food and Drug Administration ("FDA") withdrew dextropropoxyphene ("DPP") from the United States ("US") market. The FDA determined that the benefits of DPP for pain relief at US recommended doses are outweighed by the safety risk and as such the regulator requested that suppliers voluntarily withdraw any drugs containing DPP from the US market.

RSS feed

 

Doxyfene